home
  • News Releases

News Releases

2019

2019-12-10

Maruho Enters an Exclusive License Agreement in Japan for SP-04, a Therapeutic Agent for Chemotherapy Induced Peripheral Neuropathy, and a Capital Alliance with Solasia

2019-12-02

Chugai Completes Transfer of Rights to Maruho for Oxarol® Ointment 25μg/g and Oxarol® Lotion 25μg/g, Therapeutic Agents for Keratosis including Psoriasis Vulgaris, and Marduox® Ointment, a Therapeutic Agent for Psoriasis Vulgaris

2019-11-15

Maruho Establishes New Research Base -Installation of Satellite Lab at Shonan iPark-

2019-09-09

Maruho Preparing to Resume US Development For Anti-Herpes Virus Agent “Amenalief® Tab. 200mg”

2019-07-31

Maruho and KOSÉ Establish a Jointly Owned Company

2019-07-01

Maruho Establishes New US Subsidiary,“Maruho America Inc.”

2019-05-29

Maruho and Welby Launch Smartphone App “Atopi Note” to Support Patients with Atopic Dermatitis

2019-04-18

Nemolizumab Achieves Primary Endpoint in Phase 3 Clinical Study (Comparative Study) in Japan for the Treatment of Atopic Dermatitis

2019-03-29

Maruho Announces a Transfer of Shares and a Change of a Consolidated Subsidiary

2019-03-04

Maruho and Welby Launch Smartphone App “Nikibi Log” For Patients with Acne

2019-02-21

Maruho and Asahi Kasei Pharma Announce First Approval in Japan of an Additional Dosage and Administration for Anti-herpes Virus Agent "Famvir® Tab 250 mg" for the Treatment of Recurrent Herpes Simplex (Herpes labialis/Herpes genitalis)

2019-01-31

Maruho and KOSÉ Agree to Establish a Jointly Owned Company

2019-01-30

Chugai Transfers Rights to Maruho for Oxarol® Ointment 25μg/g and Oxarol® Lotion 25μg/g, Therapeutic Agents for Keratosis including Psoriasis Vulgaris, and Marduox® Ointment, a Therapeutic Agent for Psoriasis Vulgaris

Page top